{"entity":{"id":"huabo-biopharm","kind":"company","name":"Huabo Biopharm","aka":["Shanghai Huaota Biopharmaceutical","Huaota Biopharm","华奥泰生物"],"tldr":"Huabo Biopharm is a Shanghai antibody company whose bispecific HB0036 blocks PD-L1 and TIGIT at once so that exhausted T cells can attack the tumour.","summary":"Huabo Biopharm (Shanghai Huaota Biopharmaceutical) is a Shanghai-based developer of monoclonal and bispecific antibodies. Its oncology pipeline includes HB0036, a bispecific antibody against PD-L1 and TIGIT that is in phase 1/2 trials in advanced solid tumours including non-small cell lung cancer, alongside HB0025 (PD-L1 and VEGF) and HB0017, an IL-17A antibody for psoriasis.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["hb0036"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/huabo-biopharm/","neighbours":{"drug":[{"id":"hb0036","kind":"drug","name":"HB0036","route":"/drugs/hb0036/"}],"trial":[{"id":"nct05417321","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","route":"/trials/nct05417321/"},{"id":"nct07376629","kind":"trial","name":"A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC","route":"/trials/nct07376629/"},{"id":"nct06758557","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor","route":"/trials/nct06758557/"},{"id":"nct07360132","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous","route":"/trials/nct07360132/"},{"id":"nct07383116","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No","route":"/trials/nct07383116/"}]}}